cbdMD (YCBD) Amortization of Deferred Charges (2016 - 2017)
cbdMD's (YCBD) quarterly Amortization of Deferred Charges came in at $148515.0 in Q2 2017, up 91.61% quarter-over-quarter from $77511.0 in Q1 2017.
cbdMD (YCBD) Amortization of Deferred Charges (2016 - 2017) Analysis & Trends
cbdMD has disclosed Amortization of Deferred Charges across 2 years of filings, most recently posting $148515.0 for Q2 2017.
- Amortization of Deferred Charges for Q2 2017 came in at $148515.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2018 was $148515.0 (changed N/A YoY), and the FY2019 annual result was -$30000.0, changed N/A from the prior year.
- Amortization of Deferred Charges came in at $148515.0 for Q2 2017 at cbdMD, up from $77511.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $148515.0 in Q2 2017 to a low of $77511.0 in Q1 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | cbdMD | 3,905.91 | -3.38 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 148,515.00 |
| Jun 30, 2017 | 148,515.00 |
| Mar 31, 2017 | 77,511.00 |
| Mar 31, 2017 | 77,511.00 |
| Dec 31, 2016 | 79,774.00 |
| Dec 31, 2016 | 79,774.00 |